Streetbeat News

Revenues

ITOS

iTeos Therapeutics has outlined its strategic priorities for 2024, including anticipated clinical data readouts for its TIGIT program and adenosine portfolio. The company expects its cash balance of $644.9M as of September 30, 2023, to fund operations through 2026. Key milestones include Phase 2 trials for belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC, and Phase 2 and Phase 1 trials for inupadenant and EOS-984, respectively.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:45 pm

GCO

Genesco Inc (NYSE:GCO) shares dropped after reporting a 4% decline in comparable sales and reducing its FY24 EPS outlook from $1.50-$2.00 to $0.65-$0.85, against an estimate of $1.73. The company experienced a slowdown in holiday sales, particularly at Journeys stores, although Johnston & Murphy and online businesses performed well. Q3 net sales fell 4% Y/Y to $579.3 million, below the consensus of $583.0 million, and adjusted EPS of $0.57 missed the consensus of $0.82. GCO shares fell 12.40% in premarket trading.

Portfolio Pulse from Lekha Gupta

January 08, 2024 | 1:42 pm

BTCUSD

A study by Coingecko Research based on Google Trends data from January 2019 to January 2024 shows Luxembourg, St. Helena, Singapore, and Switzerland have the highest interest in Bitcoin ETFs, surpassing the US, which ranks 12th. The US shows relatively even interest across states, with Nevada leading. The study also notes that 4 of the top 15 interested countries already have spot Bitcoin ETFs. BTC price is up 1.6% at $45,003.

Portfolio Pulse from Mehab Qureshi

January 08, 2024 | 1:42 pm

IRTC

iRhythm Technologies, Inc. (NASDAQ:IRTC) reported preliminary Q4 2023 results at the J.P. Morgan Healthcare Conference, showing over 22% YoY growth in patient registrations. The company expects FY24 revenue to be between $575M-$585M, aligning with estimates. iRhythm published the CAMELOT study, submitted a 510(k) to the FDA, received CE marks for Zio Monitor and ZEUS systems, and closed a $150M term loan credit facility with Braidwell LP. The company is focusing on expanding its cardiology and primary care channels and international markets, while investing in technology and growth.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:41 pm

CVRX

CVRx reported Q4 revenue of $11.2M-$11.3M, surpassing the $10.84M estimate. FY23 revenue is projected to be $39.2M-$39.3M, slightly above the $38.84M estimate. Q1 revenue is expected to be $11M-$12M, which may not meet the $11.61M estimate. FY24 revenue is forecasted to be $53M-$57M, compared to the $54.85M estimate.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:41 pm

HSAI

Hesai Technology (NASDAQ:HSAI) announced two new ADAS lidar products, the AT512 and ET25, and the completion of its 'Maxwell' R&D and manufacturing center. The AT512 offers a 300m range at 10% reflectivity, with a record 12.3 million points per second, while the ET25 is an ultra-thin lidar with a 250m range. The 'Maxwell' center features advanced lidar testing and smart industrial robots for automated production. Hesai has also won a lidar design contract with a global OEM and has delivered 300,000 units to date, with 50,000 in December alone.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:39 pm

TMCI

Treace Medical Concepts, Inc. (TMCI) reported preliminary Q4 FY23 revenue between $61.8M-$62.2M, surpassing the consensus estimate of $58.89M. The company also projected FY23 revenues to be between $186.7M-$187.1M, which is higher than the consensus of $183.86M. TMCI saw a record high average revenue per Lapiplasty procedure kit sold at approximately $6,437, marking a 9% increase from the previous year. The company also reported a significant growth in active surgeons using their products, with about 164 new additions in Q4 and 468 for the full year, ending with approximately 2,855 active surgeons, a 20% increase from the previous year. Additionally, TMCI ended Q4 with 227 direct quota carrying sales representatives, a 35% increase from the end of 2022, contributing to 82% of the revenue in Q4.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:36 pm

STIM

Neuronetics reports preliminary Q4 total revenue exceeding $20M, aligning with its previously stated guidance range of $19M-$21M.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:36 pm

SIBN

SI-BONE, Inc. has announced its preliminary revenue for the fiscal year 2023, which is expected to be between $138.5 million and $138.7 million. This forecast surpasses the estimated revenue of $136.14 million by analysts.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:33 pm

SIBN

SI-BONE, Inc. has announced preliminary Q4 revenue estimates of $38.5M-$38.7M, surpassing the expected $36.54M by analysts. This indicates a potential increase in demand for the company's products and a positive financial performance.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:32 pm